Cetera Investment Advisers
KRYS icon

Cetera Investment Advisers’s Krystal Biotech KRYS Stock Holding History

Cetera Investment Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
8,361
+2,155
+35% +$644K ﹤0.01% 2011
2026
Q1 		$1.6M Buy
6,206
+1,590
+34% +$423K ﹤0.01% 2486
2025
Q4 		$1.14M Buy
4,616
+118
+3% +$24.8K ﹤0.01% 2710
2025
Q3 		$794K Buy
4,498
+154
+4% +$23.1K ﹤0.01% 2987
2025
Q2 		$597K Buy
4,344
+2,255
+108% +$331K ﹤0.01% 2823
2025
Q1 		$377K Sell
2,089
-87
-4% -$14.6K ﹤0.01% 3083
2024
Q4 		$341K Buy
2,176
+31
+1% +$5.5K ﹤0.01% 3001
2024
Q3 		$390K Buy
2,145
+561
+35% +$108K ﹤0.01% 2859
2024
Q2 		$291K Buy
1,584
+449
+40% +$75.4K ﹤0.01% 3056
2024
Q1 		$202K Buy
+1,135
New +$158K ﹤0.01% 3343

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cetera Investment Advisers's KRYS Position: Q2 2026 in Review

Cetera Investment Advisers increased its Krystal Biotech (KRYS) stake by 35% in Q2 2026, buying an estimated $644K and bringing the position to 8,361 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Cetera Investment Advisers first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cetera Investment Advisers held 8,361 shares of Krystal Biotech worth $3.11M as of Q2 2026.
  • Cetera Investment Advisers bought 2,155 Krystal Biotech shares in Q2 2026, an estimated $644K.
  • Krystal Biotech made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2011 holding.
  • Cetera Investment Advisers first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.